Table of Contents
ISRN Psychiatry
Volume 2012 (2012), Article ID 451865, 9 pages
http://dx.doi.org/10.5402/2012/451865
Research Article

Synergistic Effect between Maternal Infection and Adolescent Cannabinoid Exposure on Serotonin 5HT1A Receptor Binding in the Hippocampus: Testing the “Two Hit” Hypothesis for the Development of Schizophrenia

1Schizophrenia Research Institute, Sydney, NSW 2010, Australia
2Department of Psychiatry and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
3Australian Nuclear Science and Technology Organisation, Lucas Heights, NSW 2234, Australia
4Laboratory of Neuroimmunology, School of Psychology, The University of Newcastle Australia, Newcastle, NSW 2300, Australia
5School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia
6Schizophrenia Research Laboratory, Neuroscience Research Australia, Randwick, NSW 2031, Australia

Received 15 March 2012; Accepted 10 April 2012

Academic Editors: B. Biancosino, C. M. Contreras, C. Eggers, and A. Michael

Copyright © 2012 Victoria S. Dalton et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Tandon, M. S. Keshavan, and H. A. Nasrallah, “Schizophrenia, "Just the Facts": what we know in 2008. Part 1: Overview,” Schizophrenia Research, vol. 100, no. 1–3, pp. 4–19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. P. H. Patterson, “Maternal effects on schizophrenia risk,” Science, vol. 318, no. 5850, pp. 576–577, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. U. Meyer and J. Feldon, “Epidemiology-driven neurodevelopmental animal models of schizophrenia,” Progress in Neurobiology, vol. 90, no. 3, pp. 285–326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Shi, N. Tu, and P. H. Patterson, “Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus,” International Journal of Developmental Neuroscience, vol. 23, no. 2-3, pp. 299–305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Winter, A. Djodari-Irani, R. Sohr et al., “Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia,” International Journal of Neuropsychopharmacology, vol. 12, no. 4, pp. 513–524, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Henquet, L. Krabbendam, J. Spauwen et al., “Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people,” British Medical Journal, vol. 330, no. 7481, pp. 11–14, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Abi-Dargham, M. Laruelle, G. K. Aghajanian, D. Charney, and J. Krystal, “The role of serotonin in the pathophysiology and treatment of schizophrenia,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 9, no. 1, pp. 1–17, 1997. View at Google Scholar · View at Scopus
  8. P. W. J. Burnet, S. L. Eastwood, and P. J. Harrison, “5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia,” Neuropsychopharmacology, vol. 15, no. 5, pp. 442–455, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. J. N. Joyce, A. Shane, N. Lexow, A. Winokur, M. F. Casanova, and J. E. Kleinman, “Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics,” Neuropsychopharmacology, vol. 8, no. 4, pp. 315–336, 1993. View at Google Scholar · View at Scopus
  10. M. D. C. Simpson, D. I. Lubman, P. Slater, and J. F. W. Deakin, “Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia,” Biological Psychiatry, vol. 39, no. 11, pp. 919–928, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Ohno, “Therapeutic Role of 5-HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease,” CNS Neuroscience and Therapeutics, vol. 17, no. 1, pp. 58–65, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. S. H. Fatemi, T. J. Reutiman, T. D. Folsom et al., “Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders,” Schizophrenia Research, vol. 99, no. 1–3, pp. 56–70, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Wang, J. Y. Yan, Y. K. Lo, P. M. Carvey, and Z. Ling, “Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide,” Brain Research, vol. 1265, pp. 196–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Abazyan, J. Nomura, G. Kannan et al., “Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology,” Biological Psychiatry, vol. 68, no. 12, pp. 1172–1181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Piontkewitz, M. Arad, and I. Weiner, “Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia,” Schizophrenia Bulletin, vol. 37, no. 6, pp. 1257–1269, 2011. View at Google Scholar
  16. U. Meyer, E. Spoerri, B. K. Yee, M. J. Schwarz, and J. Feldon, “Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia,” Schizophrenia Bulletin, vol. 36, no. 3, pp. 607–623, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Nakazi, U. Bauer, T. Nickel, M. Kathmann, and E. Schlicker, “Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 361, no. 1, pp. 19–24, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Egashira, K. Mishima, S. Katsurabayashi et al., “Involvement of 5-hydroxytryptamine neuronal system in Δ9-tetrahydrocannabinol-induced impairment of spatial memory,” European Journal of Pharmacology, vol. 445, no. 3, pp. 221–229, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. E. T. Tzavara, R. J. Davis, K. W. Perry et al., “The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions,” British Journal of Pharmacology, vol. 138, no. 4, pp. 544–553, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. N. Hill, D. J. Froc, C. J. Fox, B. B. Gorzalka, and B. R. Christie, “Prolonged cannabinoid treatment results in spatial working memory deficits and impaired long-term potentiation in the CA1 region of the hippocampus in vivo,” European Journal of Neuroscience, vol. 20, no. 3, pp. 859–863, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Zavitsanou, H. Wang, V. S. Dalton, and V. Nguyen, “Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats,” Neuroscience, vol. 169, no. 1, pp. 315–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. S. L. Andersen, “Trajectories of brain development: point of vulnerability or window of opportunity?” Neuroscience and Biobehavioral Reviews, vol. 27, no. 1-2, pp. 3–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. L. P. Spear, “The adolescent brain and age-related behavioral manifestations,” Neuroscience and Biobehavioral Reviews, vol. 24, no. 4, pp. 417–463, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Watanabe, T. Someya, and H. Nawa, “Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models,” Psychiatry and Clinical Neurosciences, vol. 64, no. 3, pp. 217–230, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. M. Samuelsson, E. Jennische, H. A. Hansson, and A. Holmäng, “Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABAA dysregulation and impaired spatial learning,” American Journal of Physiology, vol. 290, no. 5, pp. R1345–R1356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Scarr, G. Pavey, D. Copolov, and B. Dean, “Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects,” Schizophrenia Research, vol. 71, no. 2-3, pp. 383–392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Ishibashi, T. Horisawa, K. Tokuda et al., “Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 1, pp. 171–181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Ishiyama, K. Tokuda, T. Ishibashi, A. Ito, S. Toma, and Y. Ohno, “Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test,” European Journal of Pharmacology, vol. 572, no. 2-3, pp. 160–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Nakamura, M. Ogasa, J. Guarino et al., “Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial,” Journal of Clinical Psychiatry, vol. 70, no. 6, pp. 829–836, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Müller and M. J. Schwarz, “The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression,” Molecular Psychiatry, vol. 12, no. 11, pp. 988–1000, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Moranta, S. Esteban, and J. A. García-Sevilla, “Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 369, no. 5, pp. 516–524, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. A. K. Walker, T. Nakamura, R. J. Byrne et al., “Neonatal lipopolysaccharide and adult stress exposure predisposes rats to anxiety-like behaviour and blunted corticosterone responses: implications for the double-hit hypothesis,” Psychoneuroendocrinology, vol. 34, no. 10, pp. 1515–1525, 2009. View at Publisher · View at Google Scholar · View at Scopus